Open an account

Insmed

INSM · NASDAQ

$95.67+$0.38 (+0.40%)TodayMarket closed ·
Prev close $95.29

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,664 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.

Employees
1,664
Headquarters
Bridgewater, New Jersey
Listed
Feb 15, 1991
Sector
Health Care
Industry
Biotechnology
Website
insmed.com

INSM key statistics

Market cap
20.81B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.87M
Volume
2.61M
Open price
$95.44
High today
$97.20
Low today
$94.60
52 Week high
$212.75
52 Week low
$90.39

Insmed (INSM) at a glance

Insmed (INSM) last traded at $95.67, with a market cap of 20.81B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $94.60 and $97.20. The current price is 1.1% above the day's low and 1.6% below its high.

Volume so far is 2.61M shares, in line with the average of 2.87M shares a day.

Over the past year Insmed has ranged from $90.39 to $212.75, and now sits 4% of the way up that range.

Insmed met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.06 per share against an estimate of -$0.7997.

The average analyst price target is $201.84, 111.0% above the current price, from 24 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

96%of 24 analyst ratings say Buy
  • Buy95.8%
  • Hold4.2%
  • Sell0.0%
Price target · 26 analystsAvg $201.84
Low
$170.69
Now
$95.67
High
$255.15

INSM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 57.4% on average.

  1. Q3 FY24: reported -$1.27 per share against an estimate of -$1.24
  2. Q4 FY24: reported -$1.32 per share against an estimate of -$1.19
  3. Q1 FY25: reported -$1.42 per share against an estimate of -$1.36
  4. Q2 FY25: reported -$1.70 per share against an estimate of -$1.32
  5. Q3 FY25: reported -$1.75 per share against an estimate of -$1.37
  6. Q4 FY25: reported -$1.54 per share against an estimate of -$1.32
  7. Q1 FY26: reported -$0.76 per share against an estimate of -$0.9786
  8. Q2 FY26: reported -$0.06 per share against an estimate of -$0.7997

INSM news

  • Press releasePRNewswire

    Insmed Appoints Two New Directors to Its Board

  • Press releasePRNewswire

    Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

  • Press releasePRNewswire

    Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

  • Press releasePRNewswire

    Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

  • Vandana Singh

    Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed

  • Press releasePRNewswire

    Insmed Announces CFO Transition

  • Press releasePRNewswire

    FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

  • Press releasePRNewswire

    Insmed Expands Community Impact During Fifth Annual Global Day of Good

Similar companies

Companies in the same industry as Insmed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.